Landiolol is under clinical development by Perrigo Co and currently in Pre-Registration for Supraventricular Tachycardia. According to GlobalData, Pre-Registration drugs for Supraventricular Tachycardia have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Landiolol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Landiolol overview

Landiolol (AOP-200704/Rapibloc/ Landiobloc) is a cardiovascular agent. It is formulated as concentrate and powder for solution for intravenous route of administration. Rapibloc is indicated for treatment of supraventricular tachycardia and rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable, and indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention, It is not intended for use in chronic settings.

It is under development for treatment of  dobutamine-induced supraventricular tachycardia (arrhythmias), atrial fibrillation and atrial flutter. It is administered through intravenous route.

Perrigo Co overview

Perrigo Co (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic, specialty pharmaceutical company, nutritional products, and infant formulas and foods. The company’s major products include analgesics, gastrointestinal, personal care and derma therapeutics, colobetasol spray, clindamycin foam, mupirocin ointment, Ketoconazole, halobetasol ointment and cream and permethrin cream. It markets products through wholesalers, retail drugs, supermarket and mass merchandise chains and direct sales representatives. The company has its operational presence in various geographical regions such as North America, Europe, Australia, Israel, and China. Perrigo is headquartered in Dublin, Ireland.

For a complete picture of Landiolol’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.